Releasing an immune brake
Checkpoint inhibitors block signals that restrain an immune response. In suitable cancers, this can help T cells attack tumor cells. It is not a general immune booster. Some patients have durable control; others do not respond or progress early. The drug, cancer type and combination partner matter.
Source [1]
Biomarkers and medical history
PD-L1 testing, mismatch-repair status or microsatellite instability can guide treatment in specific settings. The relevant assay and threshold depend on the cancer and drug. A negative PD-L1 result does not exclude every immune-based regimen; a high result does not guarantee benefit.
Autoimmune disease, organ transplantation, prior immune toxicity, infections and current steroids require careful review. In cancers with an actionable driver, the sequence of targeted therapy and immunotherapy deserves particular attention.
PD-L1, MSI and a driver mutation answer different questions
PD-L1 describes a staining result; MSI/dMMR reflects impaired DNA mismatch repair. Neither is a universal yes/no switch for all immunotherapy. A treatment recommendation should name the cancer, assay, cutoff and combination that support it. In driver-positive lung cancer, an attractive PD-L1 result should not obscure the targeted-treatment pathway.
Source [4]
Global treatment frontiers
The next step in immunotherapy is increasingly tested against an active immune treatment, rather than chemotherapy alone. HARMONi-2 compared ivonescimab with pembrolizumab, asking whether VEGF blockade can strengthen PD-1 treatment in a defined lung-cancer population. Its 2026 survival update provides a concrete example of a China-led program informing the international treatment discussion.
The same principle is now being tested in gastric cancer through COMPASSION-37, a global Phase III study of cadonilimab-based treatment with nivolumab-containing and chemotherapy comparators. Until results are available, existing approvals and evidence should be considered separately from the study’s hypothesis.
Single drugs and combinations
Treatment may be given alone, with chemotherapy, with a second immune agent or with another targeted medicine. Early scans and clinical review assess whether the strategy is working. Apparent radiologic enlargement has several explanations; suspected pseudoprogression must be assessed in context and must not justify ignoring clinical deterioration.
Separate unusual scan findings from true deterioration
Pseudoprogression is a possibility, not the default explanation. The team may use symptoms, examination and repeat imaging to resolve uncertainty in a clinically stable patient. Worsening breathing, pain or organ function requires prompt assessment rather than automatic continuation in the hope that the scan is misleading.
Source [1]
Recognizing inflammation early
Immune toxicity can affect the skin, bowel, liver, lungs, endocrine glands, kidneys, nerves or heart. Symptoms may appear after treatment has stopped. Persistent diarrhea, new breathlessness, severe weakness, chest pain or confusion warrant prompt medical contact.
Treatment of toxicity can require interruption and immune-suppressing medicines. The need for steroids does not mean a patient has failed; protecting organ function is part of treatment.
Some warning signs do not feel like cancer symptoms
- Persistent diarrhea or blood in stool: report the change from your usual bowel pattern.
- New breathlessness, chest pain or marked muscle weakness: seek urgent assessment.
- Severe fatigue with headache, dizziness or unusual thirst: endocrine injury may need testing.
- Tell clinicians outside your cancer center the drug name and last dose; immune toxicity can occur after treatment stops.
Treating toxicity and deciding whether to restart
An organ complication may need treatment interruption, corticosteroids or other specialist care. Some endocrine problems require long-term hormone replacement. Whether immunotherapy can resume depends on the organ involved, severity, recovery and alternatives; a previously manageable rash does not predict that later organ inflammation will be mild.
Source [5]
Estimated total treatment cost
Immunotherapy costs vary by medicine and treatment combination. The ranges below cover tislelizumab and pembrolizumab, either alone or with conventional chemotherapy.
| Treatment plan | Estimated total cost |
|---|---|
| Tislelizumab alone | US$8,000–29,000 |
| Tislelizumab with conventional chemotherapy | US$12,000–48,000 |
| Pembrolizumab alone | US$33,000–80,000 |
| Pembrolizumab with conventional chemotherapy | US$37,000–100,000 |
What’s included
These are estimates of total medical treatment costs for the listed plans. In addition to the named medicines and chemotherapy where specified, they include specialist consultations and assessment, pretreatment tests, routine laboratory and imaging follow-up as needed, treatment administration and nursing, necessary hospitalization and monitoring, and routine supportive care. Travel and accommodation are not included.
Your individual treatment costs
Many ongoing drug treatments do not have a fixed treatment duration, while some regimens have a defined course. Costs accumulate with the treatments received and vary with dose, combination medicines, response and care needs. Other checkpoint inhibitors, dual immunotherapy and additional targeted medicines require a separate estimate. These ranges are indicative only; individual costs may fall outside them. Contact us for a personalized cost estimate based on your medical needs and specialist assessment.
Evidence & sources
Prepared by Chirona’s content team from the sources below. This guide supports a discussion with your treating team; it does not determine an individual treatment plan.